Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
企業コードPLUR
会社名Pluri Inc
上場日Dec 10, 2007
最高経営責任者「CEO」Mr. Yaky Yanay
従業員数106
証券種類Ordinary Share
決算期末Dec 10
本社所在地Matam Advanced Technology Park
都市HAIFA
証券取引所NASDAQ Capital Market Consolidated
国Israel
郵便番号3508409
電話番号972747108600
ウェブサイトhttps://pluri-biotech.com/
企業コードPLUR
上場日Dec 10, 2007
最高経営責任者「CEO」Mr. Yaky Yanay
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし